Q4 2024 · 13F-HR
Caligan Partners LPholdings as filed
Filed 2025-02-14 · accession 0001420506-25-000624
$394.9M
Reported value
14
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $115.5M | 29.3% | 8,118,592 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $66.7M | 16.9% | 1,436,878 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $50.8M | 12.9% | 1,525,730 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $29.7M | 7.53% | 2,692,388 | Common | SOLE |
| 035255108 | ANIK | ANIKA THERAPEUTICS INC | $23.6M | 5.98% | 1,435,130 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $22.5M | 5.71% | 2,995,932 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $20.6M | 5.21% | 626,280 | Common | SOLE |
| 78667J108 | SG7 | SAGE THERAPEUTICS INC | $16.6M | 4.20% | 3,052,538 | Common | SOLE |
| 984241109 | YMABUSD | Y-MABS THERAPEUTICS INC | $13.8M | 3.51% | 1,767,982 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $12.4M | 3.15% | 1,011,155 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $10.7M | 2.72% | 255,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $5.5M | 1.39% | 752,167 | Common | SOLE |
| 92511W108 | — | VERRICA PHARMACEUTICALS INC | $5.2M | 1.32% | 7,429,687 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $1.1M | 0.27% | 184,826 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.